BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-14 06:00 |
BerGenBios resultater for fjerde kvartal 2023: Fokusert strategi gir momentum
|
English | 972.0 KB | ||
| 2024-02-14 06:00 |
BerGenBio's Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum
|
English | 5.3 KB | ||
| 2024-02-14 06:00 |
BerGenBios resultater for fjerde kvartal 2023: Fokusert strategi gir momentum
|
Norwegian | 5.4 KB | ||
| 2024-02-07 11:00 |
BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bem…
|
English | 4.7 KB | ||
| 2024-02-06 06:00 |
BerGenBio ASA: Invitation to fourth quarter 2023 results webcast
|
English | 3.8 KB | ||
| 2024-01-05 16:14 |
BerGenBio ASA – Disclosure of large shareholding
|
English | 807 bytes | ||
| 2023-12-15 15:48 |
BerGenBio announces closure of EU-SolidAct bemcentinib study arm in hospitalize…
|
English | 3.6 KB | ||
| 2023-12-12 06:00 |
BerGenBio to Present at DNB Nordic Healthcare Conference
|
English | 2.5 KB | ||
| 2023-12-11 06:00 |
BerGenBio Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at …
|
English | 4.3 KB | ||
| 2023-12-08 17:10 |
BerGenBio ASA: Grant of share options
|
English | 105.5 KB | ||
| 2023-12-08 17:10 |
BerGenBio ASA: Grant of share options
|
English | 2.8 KB | ||
| 2023-12-08 07:33 |
BerGenBio ASA - New share capital registered
|
English | 2.0 KB | ||
| 2023-12-07 13:05 |
BerGenBio ASA: Approval and publication of prospectus
|
English | 9.5 KB | ||
| 2023-12-07 09:47 |
BerGenBio ASA - Updated timeline for delivery of new shares
|
English | 9.4 KB | ||
| 2023-11-30 16:30 |
BerGenBio ASA - Final results for the first exercise period for warrants issued…
|
English | 10.7 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
